Baxter, Cerus Platelet Viral Inactivation System Enters Phase III Trial
This article was originally published in The Gray Sheet
Baxter's Fenwal Division plans to manufacture, market and distribute a system intended to inactivate viruses, bacteria and other pathogens in platelet concentrations.
You may also be interested in...
Nexell Therapeutics plans to file two premarket approval applications in the second half of 2001 to expand labeling for its Isolex 300i magnetic cell selection system, which gained FDA approval July 6.
Baxter will distribute Cellpro's Ceprate stem cell concentration system worldwide pending approval of Nexell's Isolex stem cell collection system under a bankruptcy plan for CellPro.
Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.